UPDATE 2-Anadys hep C drug shows promise in mid-stage trial

* Says 75 pct achieved undetectable levels of virus

* Says ANA598 at 200 mg the most attractive agent

* Shares up 9 pct
(Adds details, updates share movement)

May 21 (BestGrowthStock) – Anadys Pharmaceuticals Inc (ANDS.O: ) said
its experimental hepatitis C drug showed positive early
response rates in a mid-stage trial, sending its shares up as
much as 9 percent.

The company said 75 percent of patients who received 400
milligrams of Anadys’ ANA598 twice daily for 12 weeks in
combination with standard treatments achieved undetectable
levels of the virus.

In February, the company said 73 percent of patients
achieved undetectable levels of the virus in a similar study
using a 200 mg dose of the drug. [ID:nN24199677]

However, 63 percent of patients who received a dummy drug
with standard treatments showed undetectable levels of the
virus.

Anadys said 56 percent of patients in the placebo control
arm have the specific genotype that appears to respond most
favorably to the standard treatment, while in the ANA598
treated arm 21 percent patients have that specific genotype.

“Coupled with the favorable tolerability profile seen at
200 mg bid, we believe that these results establish ANA598 at
200 mg bid as one of the most attractive agents in Phase 2 HCV
development today,” Chief Executive Steve Worland said.

Anadys said both doses of ANA598 demonstrated a favorable
safety and tolerability profile through 12 weeks.

Shares of the company were up 5 percent at $2.36 in morning
trade Friday on Nasdaq. They touched a high of $2.45 earlier in
the session.

Stock Market Investing

(Reporting by Anand Basu in Bangalore; Editing by Vinu
Pilakkott and Don Sebastian)

UPDATE 2-Anadys hep C drug shows promise in mid-stage trial